NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $3.58 +0.01 (+0.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.58▼$3.6550-Day Range$3.26▼$3.7052-Week Range$2.42▼$5.81Volume18,513 shsAverage Volume59,301 shsMarket Capitalization$91.97 millionP/E Ratio89.50Dividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Eton Pharmaceuticals alerts: Email Address Eton Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside151.4% Upside$9.00 Price TargetShort InterestHealthy0.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.42 out of 5 starsMedical Sector302nd out of 936 stocksPharmaceutical Preparations Industry140th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Eton Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.25% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently decreased by 14.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETON. Previous Next 3.2 News and Social Media Coverage News SentimentEton Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eton Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.89% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is 89.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is 89.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 169.33.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 5.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Eton Pharmaceuticals Stock (NASDAQ:ETON)Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Read More ETON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETON Stock News HeadlinesJuly 25 at 3:37 PM | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Indivior (INDV)July 23 at 2:53 AM | americanbankingnews.comEton Pharmaceuticals (NASDAQ:ETON) Trading Up 0.3%July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 15, 2024 | globenewswire.comEton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)May 23, 2024 | msn.comHarrow (NASDAQ:HROW) Stock Surges on Successful Product LaunchMay 12, 2024 | finance.yahoo.comEton Pharmaceuticals First Quarter 2024 Earnings: EPS Beats ExpectationsMay 10, 2024 | finance.yahoo.comQ1 2024 Eton Pharmaceuticals Inc Earnings CallMay 9, 2024 | globenewswire.comEton Pharmaceuticals Reports First Quarter 2024 Financial ResultsJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Eton Pharmaceuticals's earnings reportMay 7, 2024 | msn.comCraig-Hallum Initiates Coverage of Eton Pharmaceuticals (ETON) with Buy RecommendationMay 1, 2024 | globenewswire.comEton Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceMay 1, 2024 | finance.yahoo.comPhenylketonuria (PKU) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor TypeApril 30, 2024 | markets.businessinsider.comEton Pharmaceuticals Announces NDA Submission For ET-400April 30, 2024 | globenewswire.comEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)April 29, 2024 | globenewswire.comEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 26, 2024 | msn.comPE Advent International queues up for a stake in Apollo 24/7March 22, 2024 | markets.businessinsider.comEton Pharma Buys U.S. Rights To PKU GOLIKE From Relief TherapeuticsSee More Headlines Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETON CUSIPN/A CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+151.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio89.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$-940,000.00 Net Margins2.66% Pretax Margin3.38% Return on Equity5.65% Return on Assets2.92% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.43 Sales & Book Value Annual Sales$31.64 million Price / Sales2.91 Cash Flow$0.00 per share Price / Cash Flow1,110.83 Book Value$0.60 per share Price / Book5.97Miscellaneous Outstanding Shares25,690,000Free Float21,866,000Market Cap$91.97 million OptionableOptionable Beta1.29 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Sean E. Brynjelsen (Age 52)President, CEO & Director Comp: $939.42kMr. James R. Gruber CPA (Age 52)CFO, Treasurer & Secretary Comp: $554.44kMr. David C. Krempa (Age 35)Chief Business Officer Comp: $547.86kMs. Ingrid HoosSenior Vice President of Regulatory AffairsMr. Kevin GuthrieExecutive VP of Commercial OperationsKey CompetitorsAssembly BiosciencesNASDAQ:ASMBStrongbridge BiopharmaNASDAQ:SBBPSol-Gel TechnologiesNASDAQ:SLGLGlycoMimeticsNASDAQ:GLYCVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInstitutional OwnershipWestside Investment Management Inc.Bought 11,440 shares on 7/17/2024Ownership: 2.279%Opaleye Management Inc.Sold 84,106 shares on 5/29/2024Ownership: 9.520%Acadian Asset Management LLCBought 18,898 shares on 5/10/2024Ownership: 0.609%View All Institutional Transactions ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $4.38 at the beginning of 2024. Since then, ETON shares have decreased by 18.3% and is now trading at $3.58. View the best growth stocks for 2024 here. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its earnings results on Thursday, May, 9th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The firm earned $7.97 million during the quarter, compared to the consensus estimate of $8.30 million. Eton Pharmaceuticals had a net margin of 2.66% and a trailing twelve-month return on equity of 5.65%. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Top institutional investors of Eton Pharmaceuticals include Westside Investment Management Inc. (2.28%). Insiders that own company stock include Sean Brynjelsen and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO) and Vaxart (VXRT). This page (NASDAQ:ETON) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
